Learn About Myotonic Dystrophy

What is the definition of Myotonic Dystrophy?

Myotonic dystrophy is part of a group of inherited disorders called muscular dystrophies. It is the most common form of muscular dystrophy that begins in adulthood.

What are the causes of Myotonic Dystrophy?

Myotonic dystrophy type 1 is caused by mutations in the DMPK gene, while type 2 results from mutations in the CNBP gene. The protein produced from the DMPK gene likely plays a role in communication within cells. It appears to be important for the correct functioning of cells in the heart, brain, and skeletal muscles (which are used for movement). The protein produced from the CNBP gene is found primarily in the heart and in skeletal muscles, where it helps regulate the function of other genes.

How prevalent is Myotonic Dystrophy?

Myotonic dystrophy affects at least 1 in 8,000 people worldwide. The prevalence of the two types of myotonic dystrophy varies among different geographic and ethnic populations. In most populations, type 1 appears to be more common than type 2. However, recent studies suggest that type 2 may be as common as type 1 among people in Germany and Finland.

Is Myotonic Dystrophy an inherited disorder?

Both types of myotonic dystrophy are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one parent with the condition.

Who are the top Myotonic Dystrophy Local Doctors?
Elite in Myotonic Dystrophy
Elite in Myotonic Dystrophy

Penn Neuroscience Center - Neurology

330 South 9th Street, 3rd Floor, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients

Lauren Elman is a Neurologist in Philadelphia, Pennsylvania. Dr. Elman is rated as an Elite provider by MediFind in the treatment of Myotonic Dystrophy. Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Myotonic Dystrophy, and Myotonic Dystrophy Type 2. Dr. Elman is currently accepting new patients.

Elite in Myotonic Dystrophy
Elite in Myotonic Dystrophy

Ambulatory Care Center

417 N. 11th Street, 
Richmond, VA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Nicholas Johnson is a Neurologist in Richmond, Virginia. Dr. Johnson is rated as an Elite provider by MediFind in the treatment of Myotonic Dystrophy. His top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy Type 2, Myotonic Dystrophy, and Limb-Girdle Muscular Dystrophy. Dr. Johnson is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myotonic Dystrophy
Elite in Myotonic Dystrophy
Milan, IT 

Giovanni Meola practices in Milan, Italy. Mr. Meola is rated as an Elite expert by MediFind in the treatment of Myotonic Dystrophy. His top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy Type 2, Myotonic Dystrophy, Amyotonia Congenita, and Thymectomy.

What are the latest Myotonic Dystrophy Clinical Trials?
A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1

Summary: The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)

Summary: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)

Who are the sources who wrote this article ?

Published Date: July 01, 2020
Published By: National Institutes of Health